A controlled trial on Ro 5-4023 (clonazepam) in the treatment of psychomotor epilepsy.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use; D002648:Child; D002722:Chlorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010919:Placebos; D011324:Primidone / Q000627:therapeutic use; D013997:Time Factors
D000927:Anticonvulsants; D001570:Benzodiazepinones; D002722:Chlorobenzenes; D009574:Nitro Compounds; D010919:Placebos; D011324:Primidone; D002220:Carbamazepine; D010672:Phenytoin; D010634:Phenobarbital